Consensus Treace Medical Concepts, Inc.

Stocks

TMCI

US89455T1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-11-05 EST			5-day change	1st Jan Change
4.180 ^USD	-7.11%		-17.39%	+70.61%

09-17	Treace Medical Concepts Announces Results of Three Clinical Studies Including the Milestone Five-Year Align3d Study Demonstrating Sustained Positive Outcomes of the Lapiplasty Procedure	CI
09-15	Treace Medical Concepts, Inc. Highlights Product Innovations And Clinical Data Across Its Expanding Foot And Ankle Portfolio At The AOFAS Annual Meeting	CI

Evolution of the Average Target: Treace Medical Concepts, Inc.

Evolution of the Target Price: Treace Medical Concepts, Inc.

Changes in Analyst Recommendations: Treace Medical Concepts, Inc.

af425167cad2635490d0.k3TzdL3u5w_t13-dGTL2-j2KQTuXpHe-ob0KgKieivE.3hGHBfPZuDqeuDOwXkCbvVz8CF6i0AHpwvA_6vzuw4PaWcoj1rHWeqe6Rw~2046b8e124780503e63c583cd1162c3f

Analysts' recommendations: Treace Medical Concepts, Inc.

08-10	Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating	MT
07-16	Truist Securities Adjusts Price Target on Treace Medical Concepts to $4 From $2, Maintains Hold Rating	MT
03-02	Truist Securities Adjusts Treace Medical Concepts PT to $2 From $3, Maintains Hold Rating	MT
12-18	Truist Securities Trims Price Target on Treace Medical Concepts to $3 From $4, Maintains Hold Rating	MT
11-10	Truist Cuts Price Target on Treace Medical Concepts to $4 From $7, Keeps Hold Rating	MT
11-07	UBS Adjusts Price Target on Treace Medical Concepts to $5.85 From $6.50, Maintains Neutral Rating	MT
11-07	JPMorgan Downgrades Treace Medical Concepts to Underweight From Neutral, Adjusts PT to $5 From $8	MT
11-07	BTIG Research Downgrades Treace Medical Concepts to Neutral From Buy	MT
25-08-08	UBS Adjusts Treace Medical Concepts Price Target to $6.50 From $8.60, Maintains Neutral Rating	MT
25-08-07	Treace Medical Q2 revenue edges above estimates	RE
25-05-13	Morgan Stanley Cuts Price Target on Treace Medical Concepts to $8 From $10, Maintains Equalweight Rating	MT
25-05-09	UBS Adjusts Price Target on Treace Medical Concepts to $8.60 From $10, Maintains Neutral Rating	MT
25-04-11	Truist Cuts Price Target on Treace Medical Concepts to $8 From $9.50, Keeps Hold Rating	MT
25-03-13	Truist Adjusts Price Target on Treace Medical Concepts to $9.50 From $10, Maintains Hold Rating	MT
25-03-03	UBS Adjusts Treace Medical Concepts Price Target to $10 From $7.90, Maintains Neutral Rating	MT
25-02-28	Truist Securities Adjusts Price Target on Treace Medical Concepts to $10 From $8.40, Keeps Hold Rating	MT
25-02-04	BTIG Upgrades Treace Medical Concepts to Buy From Neutral, Price Target is $16	MT
24-12-31	Treace Medical Concepts Shares Rise After Lake Street Begins Coverage With Buy Rating	MT
24-12-31	Lake Street Initiates Treace Medical Concepts at Buy With $14.50 Price Target	MT
24-12-18	Truist Securities Adjusts Price Target on Treace Medical Concepts to $8.40 From $7, Keeps Hold Rating	MT
24-10-14	Truist Lowers Price Target on Treace Medical Concepts to $6 From $7.50, Keeps Hold Rating	MT
24-08-07	UBS Adjusts Treace Medical Concepts Price Target to $7 From $6.50, Maintains Neutral Rating	MT
24-08-07	Truist Securities Adjusts Price Target on Treace Medical Concepts to $7.50 From $9, Maintains Hold Rating	MT
24-07-16	Truist Raises Price Target on Treace Medical Concepts to $9 From $7, Maintains Hold Rating	MT
24-07-15	Morgan Stanley Raises Price Target on Treace Medical Concepts to $8 From $5.50, Keeps Equalweight Rating	MT

More recommendations

Medical Equipment

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TREACE MEDICAL CONCEPTS, INC.					+31.58%
	ABBOTT LABORATORIES					+4.33%
	STRYKER CORPORATION					+1.61%
	MEDTRONIC PLC					-0.21%
	ESSILORLUXOTTICA					+12.48%
	CENCORA, INC.					+9.42%
	BECTON, DICKINSON AND COMPANY					-8.42%
	IDEXX LABORATORIES, INC.					+5.68%
	HOYA CORPORATION					+27.1%
	ALCON INC.					+16.86%
	Average					+10.04%
	Weighted average by Cap.					+5.76%